TEVA
Teva Pharmaceutical Industries Ltd
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
—
Top fund weight
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
Teva Pharmaceutical Industries Ltd
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
—
Top fund weight
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
0.14%
TEVA weight · SEIE
Teva Pharmaceutical Industries has 3 disclosed suppliers and 5 disclosed customers in SEC filings.
Teva Pharmaceutical Industries Ltd
41.97
SentenceIn connection with the Teva LDA, we also entered into a product supply agreement with Teva in August 2020 (the "Teva PSA") for the manufacture and supply of each product in the Teva Territory covered by the Teva LDA. Pursuant to the Teva PSA, Teva will remit approximately 40% of its in-market sales to us in the form of sales-based royalties.
basisALVO FY2025 revenue $779MTEVA FY2025 revenue $17.3B
SentencePursuant to the terms of a confidential settlement and license agreement entered into in August 2023 with Teva, we granted Teva a non-exclusive, royalty-free, non-transferable, non-sublicensable limited license under the remaining patent covering VIVITROL to market and sell a generic version of VIVITROL in the U.S. beginning on the First Entry Date, or earlier under certain circumstances.
SentenceCEL-SCI has already licensed future sales of Multikine, if approved, to three companies: Teva Pharmaceutical Industries Ltd. in Israel, Turkey, Serbia and Croatia; Orient Europharma in Taiwan, Singapore, Hong Kong, Malaysia, South Korea, the Philippines, Australia and New Zealand; and Byron BioPharma, LLC in South Africa.
SentenceIn October 2021, we entered into an asset purchase agreement, or the Teva Agreement, with Teva Pharmaceutical Industries, Ltd. and its affiliate Cephalon, Inc., or, together Teva, pursuant to which we acquired patents, know-how and other rights to ALTO-203 and a specified related compound, or Teva Acquired Compounds, and we assumed all post-acquisition liabilities related thereto.
Expected move
Inputs8Q avg ±8.9%·×0.68·cheap
straddle ±6.3%
spot 42.09exp Nov 6ATM strike 42ATM straddle 3.12IV 67%